[The fibroblast growth factor as a predictor of symptomatic change under combined pharmacological treatment of benign prostatic hyperplasia].
The results of our study showed, that long-term combined medical treatment of benign prostatic hyperplasia (Finasteride 5 mg/day + Tamsulosin 0.4 mg/day) significantly decreases values of IPSS and residual urine volume (RUV) in patients, which basic level of bFGF in serum does not exceed 5.9 pg/ml. On the other hand pharmacological treatment was insufficient in patients with bFGF basic level equal or more than 5.9 pg/ml; values of IPSS and RUV did not decrease.
Boroian
R R
RR
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D018120:Finasteride / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000188:drug therapy*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D000077409:Tamsulosin; D016896:Treatment Outcome; D014554:Urination / Q000187:drug effects
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D013449:Sulfonamides; D016222:Fibroblast Growth Factor 2; D018120:Finasteride; D000077409:Tamsulosin